ALPS Advisors
TARA icon

ALPS Advisors’s Protara Therapeutics TARA Stock Holding History

ALPS Advisors’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$237K Buy
77,735
+20,694
+36% +$80.6K ﹤0.01% 1107
2026
Q2 		$218K Buy
57,041
+13,012
+30% +$61.9K ﹤0.01% 1152
2026
Q1 		$229K Buy
44,029
+1,640
+4% +$9.7K ﹤0.01% 988
2025
Q4 		$226K Buy
+42,389
New +$236K ﹤0.01% 965
2021
Q2 		– Sell
-20,279
Closed -$319K – 917
2021
Q1 		$319K Buy
20,279
+209
+1% +$3.88K ﹤0.01% 782
2020
Q4 		$486K Buy
+20,070
New +$433K 0.01% 502

Other funds holding TARA

Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return
Indivisible Partners
Indivisible Partners Clearwater, Florida $2.18B AUM 33.61% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Essential Partners
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

ALPS Advisors's TARA Position: Q3 2026 in Review

ALPS Advisors increased its Protara Therapeutics (TARA) stake by 36% in Q3 2026, buying an estimated $80.6K and bringing the position to 77,735 shares worth $237K. The position accounts for ﹤0.01% of the portfolio, ranked #1107.

ALPS Advisors first reported a position in TARA in Q4 2020 and has held it in 6 quarters since. The position peaked at $486K in Q4 2020. 15 funds tracked by Wall St. Rank hold TARA as of Q3 2026.

  • ALPS Advisors held 77,735 shares of Protara Therapeutics worth $237K as of Q3 2026.
  • ALPS Advisors bought 20,694 Protara Therapeutics shares in Q3 2026, an estimated $80.6K.
  • Protara Therapeutics made up ﹤0.01% of ALPS Advisors's portfolio in Q3 2026, its #1107 holding.
  • ALPS Advisors first reported a position in Protara Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • ALPS Advisors's Protara Therapeutics position peaked at $486K in Q4 2020.
  • 15 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2026.

Based on ALPS Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.